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Summary
Atrial fibrillation may be clearly symptomatic and is easily
amenable to state-of-the-art treatment, most importantly
oral anticoagulation therapy for the prevention of throm-
boembolism. However, atrial fibrillation may also go un-
noticed for long periods in many patients. This silent or
subclinical atrial fibrillation is nevertheless associated with
thromboembolic risk just like clinically evident atrial fibril-
lation. Early detection of atrial fibrillation in patients at in-
creased thromboembolic risk and consequent oral antico-
agulation therapy may have a significant impact on public
health. This review focuses on screening recommenda-
tions for atrial fibrillation and on the impact of silent atrial
fibrillation in various clinical scenarios.
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Introduction
Atrial fibrillation is an endemic disease affecting 3% of the
adult population with a prevalence of about 1% at the age
of 60 years, increasing to >15% at the age of 85 years [1].
The number of patients affected by atrial fibrillation is ex-
pected to double by the year 2050 because of the aging
population [2]. Atrial fibrillation is the leading cause of is-
chaemic stroke and is highly prevalent in stroke patients,
with prevalence increasing steeply with age [3]. Atrial fib-
rillation is not only associated with an increased risk of
stroke, but also increases the risk of heart failure and all-
cause mortality [4]. Atrial fibrillation has also been linked
to silent brain lesions, as well as cognitive impairment and
dementia [5, 6]. Once atrial fibrillation is diagnosed, oral
anticoagulation therapy is initiated in most patients to pre-
vent thromboembolic events, thereby significantly lower-
ing morbidity and mortality [7].
However, atrial fibrillation is often clinically silent and
therefore not diagnosed or only discovered late, at the time
of an event such as an ischaemic stroke [8, 9]. Silent atrial
fibrillation is a challenging problem for public health: ear-
ly identification and treatment of affected subjects, maybe
even subjects at risk of atrial fibrillation, might further
lower morbidity and mortality.
Screening for atrial fibrillation in the general
population
Back in 2012, atrial fibrillation guidelines recommended
only opportunistic screening for atrial fibrillation in pa-
tients aged ≥65 years by pulse palpation followed by an
electrocardiogram in the case of an irregular pulse. With
this simple community screening approach, atrial fibrilla-
tion can be identified in about 1.4% of subjects not previ-
ously known to have atrial fibrillation [10]. And accord-
ing to the guidelines, oral anticoagulation therapy should
be considered in all of these patients, as thromboembolic
risk is elevated in patients aged ≥65 years [7]. Since 2012,
recommendations for atrial fibrillation screening have
evolved significantly as a result of various studies, which
will be presented hereafter (table 1).
More advanced, stepwise community screening was tested
in a Swedish study: screening of a population aged 75–76
years with at least one additional stroke risk factor by
means of 12-lead ECG, and, if negative, by repeat hand-
held ECG identified new atrial fibrillation in an additional
1% and 7.4% of subjects, respectively [11]. The same
group thereafter expanded the stepwise screening pro-
gramme to include 7173 subjects aged 75–76 years, ir-
Table 1: Recommendations for screening for atrial fibrillation accord-
ing to the 2016 European Society of Cardiology guidelines for the
management of atrial fibrillation.
Recommendations Class* Level†
Opportunistic screening for AF is recommended by
pulse taking or ECG rhythm strip in patients >65
years of age.
I B
In patients with TIA or ischaemic stroke, screening
for AF is recommended by short-term ECG recording
followed by continuous ECG monitoring for at least
72 hours.
I B
It is recommended to interrogate pacemakers and
ICDs on a regular basis for AHRE. Patients with
AHRE should undergo further ECG monitoring to
document AF before initiating AF therapy.
I B
In stroke patients, additional ECG monitoring by
long-term noninvasive ECG monitors or implanted
loop recorders should be considered to document
silent atrial fibrillation.
IIa B
Systematic ECG screening may be considered to
detect AF in patients aged >75 years, or those at
high stroke risk.
IIb B
AF = atrial fibrillation; AHRE = atrial high-rate episodes; ECG = electro-
cardiogram; ICD = implantable cardioverter-defibrillator; TIA = transient
ischaemic attack. * Class of recommendation; † Level of evidence
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respective of additional stroke risk factors. In this study,
new atrial fibrillation was diagnosed by ECG in 0.5% of
the cases, and by repeat hand-held ECG in 2.5% [12]. In
the above-mentioned study, the probability of diagnosing
new atrial fibrillation was higher in subjects with vascu-
lar disease, additional stroke risk factors or a high body
mass index [12]. Another approach would therefore be
to focus screening efforts on populations known to be at
higher risk of atrial fibrillation. Additional parameters that
may prove to be useful to triage patients for screening
are echocardiographic, laboratory and ECG results. For
instances, patients with a dilated left atrium, prolonged
electromechanical delay, increased high-sensitive C-reac-
tive protein (CRP), brain-type natriuretic peptide (BNP),
high-sensitive cardiac troponin or a high number of prema-
ture atrial complexes are more often found to have atrial
fibrillation during follow-up [13–19].
Nevertheless, all screening efforts for atrial fibrillation are
futile unless patients with positive screening are treated as
recommended by the guidelines. To put screening efforts
into perspective, in the Swedish study mentioned above,
2.1% of the population had known but untreated atrial fib-
rillation (half of them thereafter started oral anticoagula-
tion therapy), compared with 3% of newly diagnosed atrial
fibrillation cases [12]. To improve public health, screening
efforts are certainly needed. However, treatment of all pa-
tients known to have atrial fibrillation according to guide-
lines should be ensured in the first place.
Whether aggressive screening and treatment of atrial fibril-
lation will indeed improve outcome may also be answered
by our Swedish colleagues. They plan to compare the out-
come of screened and, if required, treated subjects with the
remaining population through the Swedish patient registry
[20]. In the meanwhile, systematic ECG screening of pa-
tients aged >75 years or at high risk of ischaemic stroke
has received a Class IIb indication in current atrial fibrilla-
tion guidelines (table 1).
Atrial fibrillation in ischaemic stroke patients
As discussed above, the prevalence of atrial fibrillation in
the general population rises steeply with age. This is also
true among ischaemic stroke patients, with the difference
that prevalence rates of atrial fibrillation are about four-
fold higher in each age group compared with the general
population [8]. Many patients with known atrial fibrillation
presenting with ischaemic stroke have received either no
anticoagulation or sub-therapeutic anticoagulation [8, 21].
These patients also have worse outcome from ischaemic
stroke than patients with atrial fibrillation and therapeu-
tic anticoagulation presenting with ischaemic stroke [21].
Again, primary emphasis from a public health standpoint
should be to treat patients known to have atrial fibrillation
according to guidelines.
Monitoring of ischaemic stroke patients for the presence of
atrial fibrillation is nevertheless mandatory: an admission
ECG will yield about 7.7% of new atrial fibrillation cas-
es, in-hospital monitoring an additional 5.1% of cases and
ambulatory Holter monitoring 10.7% [9]. Extending moni-
toring to 30 days with event-triggered recording following
an ischaemic stroke has yielded 16.1% of new atrial fibril-
lation cases [22]. With the implantation of a loop recorder,
the rate of new atrial fibrillation cases increases up to 30%
after 3 years [23]. The overall atrial fibrillation detection
rate after ischaemic stroke including admission ECG, in
hospital and ambulatory monitoring may add up to well
over 20% of cases [9]. As a result, screening for atrial
fibrillation after an ischaemic stroke by short-term ECG
recording followed by continuous ECG monitoring up to
72 hours is a class I indication in the current atrial fibrilla-
tion guidelines (table 1). Additionally, prolonged noninva-
sive monitoring or implantation of a loop recorder after an
ischaemic stroke is a class IIa indication.
Importantly, screening of atrial fibrillation in ischaemic
stroke patients should not be restricted to cryptogenic
stroke patients or patients presenting with a most probable
origin for embolic stroke according to the TOAST (Trial of
Org 10172 in Acute Stroke Treatment) classification, be-
cause competing causes of ischaemic stroke are frequently
present [24].
Studies are currently in the recruiting phase that randomise
ischaemic stroke patients without an atrial fibrillation di-
agnosis to oral anticoagulation therapy versus aspirin (Ri-
varoxaban Versus Aspirin in Secondary Prevention of
Stroke and Prevention of Systemic Embolism in Patients
With Recent Embolic Stroke of Undetermined Source
[NAVIGATE ESUS;ClinicalTrials.gov identifier:
NCT02313909] and Dabigatran Etexilate for Secondary
Stroke Prevention in Patients With Embolic Stroke of Un-
determined Source [RE-SPECT ESUS; NCT02239120]).
If these studies prove superiority of oral anticoagulation
therapy, screening for atrial fibrillation after an ischaemic
stroke may be less important in the future.
Atrial fibrillation in silent stroke patients
The prevalence of silent brain lesions is age dependent and
generally reported in the range of 10 to 20% in most stud-
ies, with an annual incidence of 2 to 4% [25, 26]. Silent
brain lesions are not harmless: patients with silent brain le-
sions have an increased risk of dementia and a steeper de-
cline in cognitive function than those without such lesions
[27]. The presence of silent brain lesions also increases the
risk of new silent brain lesions three-fold, and the risk of
symptomatic ischaemic stroke two-fold [26, 28].
On the other hand, brain imaging studies comparing pa-
tients with and without atrial fibrillation but no history of
ischaemic stroke have reported an important association of
atrial fibrillation with silent brain lesions (odds ratio 2.62,
95% confidence interval 1.81–3.80]) [5]. The prevalence
of silent brain lesions on computed tomography and mag-
netic resonance imaging among patients with atrial fibril-
lation in these studies has been reported to be 22 and 40%,
respectively [5]. Whether such silent brain lesions in atrial
fibrillation patients are cardioembolic in origin or whether
their coexistence with atrial fibrillation is simply a reflec-
tion of shared risk factors remains to be proven.
Atrial fibrillation is probably the most important cause of
cardioembolic, typically large and clinically relevant, is-
chaemic strokes. Nevertheless, cardioembolic strokes can
certainly also occlude smaller vessels, depending on the di-
ameter of the embolus. Although causes other than atrial
fibrillation may be responsible for a bigger proportion of
smaller ischaemic strokes than of larger strokes, atrial fib-
rillation may still be an important and underestimated play-
er.
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To date, no study has rigorously investigated the presence
of atrial fibrillation in patients with silent brain lesions. As
a consequence, prolonged rhythm monitoring to search for
atrial fibrillation is nowadays routinely performed in is-
chaemic stroke patients, but not in patients with silent brain
lesions.
Atrial high-rate episodes a cardiac implantable
electronic devices
The number of patients with cardiac implantable electronic
devices including an atrial lead is steadily growing. These
devices permit continuous monitoring for atrial high-rate
episodes exceeding a programmable or device-specific du-
ration. If this function is enabled, a notification will appear
upon device interrogation if an episode fulfilling pro-
grammed criteria occurred (fig. 1). Such notifications may
also be transmitted daily by remote monitoring if this fea-
ture is enabled, allowing for continuous, almost real-time
arrhythmia screening. Several studies have reported an as-
sociation of atrial high-rate episodes with clinically diag-
nosed atrial fibrillation, as well as increased risk of is-
chaemic stroke and even mortality [29–31]. Interestingly,
atrial high-rate episodes have also been reported to be an
independent predictor for silent brain lesions [32].
Different cut-offs have been used, but generally a duration
exceeding 5 to 6 minutes is accepted as a criterion for rel-
evant atrial high-rate episodes (by definition rates have to
be >180 bpm). Current guidelines have also been adapt-
ed accordingly (table 1) [7]. In the event of atrial high-rate
episodes, the presence of atrial fibrillation should be veri-
fied on a corresponding electrogram from the device (fig.
2) or on a standard ECG or rhythm strip, and anticoagula-
tion should be initiated according to guidelines. Verifica-
tion of atrial fibrillation is important, because atrial high-
rate episodes may also correspond to noise or far field elec-
trograms, etc. On an individual basis, patients with atrial
high-rate episodes at high stroke risk may also be antico-
agulated without electrogram or ECG verification of atrial
fibrillation. However, the benefit of anticoagulation in pa-
tients with atrial high-rate episodes is currently less well
established than in patients with atrial fibrillation. Sev-
eral studies currently underway are testing the benefit of
oral anticoagulation therapy in patients with atrial high rate
episodes (e.g. Apixaban for the Reduction of Thrombo-
Embolism in Patients With Device-Detected Sub-Clinical
Atrial Fibrillation [ARTESiA; NCT01938248] and Non vi-
tamin K antagonist Oral anticoagulants in patients with
Atrial High rate episodes [NOAH]; NCT02618577). How-
ever, much has still to be learned about the causal re-
lationship between atrial high-rate episodes and throm-
boembolism: many thromboembolic events in the studies
mentioned above were not temporally associated with atri-
al high-rate episodes [33, 34]. Finally, it also has to be em-
phasised that patients with cardiac implantable electronic
devices represent a very select patient population with ad-
vanced cardiac disease, and these findings cannot be gen-
eralised to other populations.
Atrial fibrillation as a causative or surrogate
factor for thromboembolic risk
As discussed above, atrial high-rate episodes and atrial
fibrillation are associated with ischaemic stroke, but the
temporal relationship is intriguingly loose. This raises the
question of whether atrial fibrillation is in fact the cause
or rather a surrogate factor of increased thromboembolic
risk. Interestingly, both the CHA2DS2-VASc score as well
as the CHADS2 score can predict ischaemic stroke events
in populations without known atrial fibrillation with sim-
ilar accuracy to that in populations with atrial fibrillation,
although the event rate is somewhat lower [35–37]. On the
other hand, frequent premature atrial contractions are also
an independent predictor of ischaemic stroke, even when
Figure 1: Example of atrial high rate episodes as displayed during interrogation of a pacemaker or an implantable cardioverter defibrillator
with an atrial lead. In this example, several atrial high rate episodes lasting from less than a minute to up to 6 hours have been registered.
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subjects are censored in the event of an atrial fibrillation
diagnosis [38]. Subjects with a CHA2DS2-VASc score ≥2
and frequent premature atrial contractions are reported to
have an ischaemic stroke risk of 2.4%, very similar to his-
torical populations with atrial fibrillation [38].
Subjects with higher CHA2DS2-VASc scores certainly
have more advanced vascular disease, which may also in-
crease thromboembolic risk independently of atrial fibril-
lation. However, except the rare cases of primary electri-
cal disease, patients with atrial fibrillation have some kind
of atrial cardiomyopathy leading to atrial fibrillation [39].
According to Virchow’s triad, haemodynamic changes, en-
dothelial injury and hypercoagulability all contribute to
thrombosis. The increased risk of thromboembolism at-
tributed to atrial arrhythmias may partly be explained by
associated haemodynamic changes. But the occurrence of
premature atrial contractions, atrial high-rate episodes and
eventually atrial fibrillation may also be interpreted as a
surrogate of more advanced atrial fibrosis and inflamma-
tion, i.e., atrial cardiomyopathy leading to endothelial in-
jury and hypercoagulability, and resultant increased throm-
boembolic risk.
Most probably, atrial fibrillation is both a causative and
a surrogate factor of increased thromboembolic risk (fig.
3). Maybe expanding the CHA2DS2-VASc score to also in-
clude premature atrial contractions or a diagnosis of atrial
fibrillation would serve well as a more general approach
for thromboembolic risk calculation in the general popula-
tion. To our knowledge, no studies are currently planned to
randomise patients with a high CHA2DS2-VASc score but
without atrial fibrillation to anticoagulation therapy versus
no therapy, except the studies of patients after ischaemic
stroke discussed above. But with the advent of the novel
oral anticoagulants, the time for such studies is probably
not so far away anymore.
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